402 Study design and rationale for the efficacy and safety assessment of daxdilimab, a selective plasmacytoid dendritic cell depleter, in a phase 2 trial of patients with moderate-to-severe primary discoid lupus erythematosus
- DOI
- 10.1136/lupus-2023-lupus21century.25
- Published
- 2024-05
- Container
- Cutaneous Lupus & Photosensitivity
- Publisher
- Lupus Foundation of America
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1136/lupus-2023-lupus21century.25,
title = {402 Study design and rationale for the efficacy and safety assessment of daxdilimab, a selective plasmacytoid dendritic cell depleter, in a phase 2 trial of patients with moderate-to-severe primary discoid lupus erythematosus},
author = {Adina K Knight and David Larson and Liangwei Wang and Linda Zhu},
year = {2024},
journal = {Cutaneous Lupus \& Photosensitivity},
doi = {10.1136/lupus-2023-lupus21century.25},
url = {https://doi.org/10.1136/lupus-2023-lupus21century.25}
}RIS
TY - JOUR TI - 402 Study design and rationale for the efficacy and safety assessment of daxdilimab, a selective plasmacytoid dendritic cell depleter, in a phase 2 trial of patients with moderate-to-severe primary discoid lupus erythematosus AU - Adina K Knight AU - David Larson AU - Liangwei Wang AU - Linda Zhu PY - 2024 JO - Cutaneous Lupus & Photosensitivity DO - 10.1136/lupus-2023-lupus21century.25 UR - https://doi.org/10.1136/lupus-2023-lupus21century.25 ER -
APA
Knight, A. K., Larson, D., Wang, L., & Zhu, L. (2024). 402 Study design and rationale for the efficacy and safety assessment of daxdilimab, a selective plasmacytoid dendritic cell depleter, in a phase 2 trial of patients with moderate-to-severe primary discoid lupus erythematosus. Cutaneous Lupus & Photosensitivity. https://doi.org/10.1136/lupus-2023-lupus21century.25
Source records
- crossref · retrieved 2026-09-27T11:07:29.111Z